Background: The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital.
Introduction
At the introduction of fluoroquinolones to the pharmaceutical market in the 1980s, it was believed, by some people, that fluoroquinolones were effective drugs that should not encounter bacterial resistance because of their complex mechanism of action and their entirely synthetic origin. 1, 2 However, the emergence and dramatic increase in isolates of fluoroquinolone-resistant Escherichia coli (FQ-R E. coli) 3 -5 have raised the issue of treatment failure in very common infections, such as urinary tract infections. Antibiotic consumption is widely recognized as the main cause of this resistance. Several studies have focused on the relationship between fluoroquinolone use and the emergence or dissemination of FQ-R E. coli, but few used adequate methods. 6 -8 Among them, studies adopting ecological designs are relevant to the assessment of this relationship because they allow a better understanding of bacterial ecology as a whole. Besides geographic correlation studies, 9 -14 some authors focused on correlation over time, 15 -19 but few reported appropriate statistical methods. Indeed, the correlation between data collected over time must be taken into account by resorting to time-series analysis. Lately, these methods have been applied to the field of microbiology. 20 -23 Antimicrobial use in the community is also believed to be an important determinant of resistance in hospitals, although very few studies have investigated the influence of outpatient consumption of fluoroquinolones on hospital FQ-R E. coli. 10, 24 As outpatient quinolone use keeps increasing despite a national campaign to reduce antibiotic use in France, 25 it is of special interest to focus on the relationship between outpatient use and hospital resistance.
The objectives of the present study were to investigate the temporal relationship between inpatient and outpatient fluoroquinolone use and FQ-R E. coli in a university hospital and to forecast resistance rates.
Methods

Design
This was an ecological study.
Setting
The study was set in the Midi-Pyrénées region (south-western France), with 2 777000 inhabitants in 2006, essentially living in rural communities within a radius of 200 km around the main town, Toulouse (which was home to 850900 inhabitants in 2006). Toulouse University Hospital (TUH) is the sole tertiary hospital of the Midi-Pyrénées region, with 2848 beds, including 101 intensive care beds, 120 critical care beds and 155 long-term beds. Around 90% of patients admitted to TUH in 2006 were living in the Midi-Pyrénées region.
Methods
The monthly FQ-R E. coli rate and fluoroquinolone use were retrospectively collected from existing sources from January 2004 to December 2007.
FQ-R E. coli
Every biological specimen that had yielded E. coli in TUH's bacteriology laboratory was systematically tested for ciprofloxacin susceptibility (except in children, fluoroquinolones not being indicated in paediatric patients). Ciprofloxacin susceptibility was used to determine the percentage of FQ-R E. coli, defined as the proportion of ciprofloxacin-resistant strains or of intermediate susceptibility to ciprofloxacin among all E. coli isolates tested for ciprofloxacin susceptibility every month. Duplicate isolates were deleted; only the first isolate of E. coli for each patient remained in the database. Susceptibility testing was performed by the disc diffusion method on Mueller -Hinton agar (BioMérieux w agar, Bio-Rad w discs) or by an automated technique (Vitek w 2, BioMérieux w ), according to the guidelines of the CLSI (formerly NCCLS). 26 Isolates were collected from both TUH inpatients and outpatients (emergency departments, outpatient clinics).
Fluoroquinolone consumption
Fluoroquinolone [identified by the code 'J01MA' in the anatomical, therapeutic and chemical (ATC) classification] use was expressed in defined daily doses (DDDs), according to the WHO manual, version 2007. 27 DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It allows the standardization of the consumption of different drugs whatever their differences in the mean prescribed daily dose. 27 A DDD of 0.4 mg was assigned to lomefloxacin (as no DDD was officially assessed). Consumption of firstgeneration quinolones (such as nalidixic acid and pipemidic acid) was not recorded.
Inpatient fluoroquinolone use was collected from dispensing data supplied by TUH's pharmacy department (number of tablets, intravenous bottles, etc.). The data were converted into DDDs/1000 inpatient-days.
Community fluoroquinolone use was approximated by reimbursement data collected from the computerized database of the major regional healthcare scheme. This database takes an inventory of all reimbursement applications for drugs for around 65% of the MidiPyrénées region population (not including reimbursements for farmers, self-employed people, students, etc.). Reimbursed quantities for the whole region's population were inferred and expressed in DDDs/1000 inhabitants/day. As drug packages are usually designed to provide a treatment course for the most common infections, when calculating DDDs we assumed that the entire drug package was consumed.
Statistical analysis
We discounted pefloxacin consumption because of its very low use, and pooled consumptions of norfloxacin, enoxacin and lomefloxacin (not available in TUH) as urinary fluoroquinolone use.
Following the method developed by Box and Jenkins, 28 we generated autoregressive integrated moving average (ARIMA) models for inpatient and outpatient use of fluoroquinolones. We computed 12 monthforecasts for these series in order to introduce them as inputs in dynamic regression (DR) models or linear transfer function models. For an introduction to time-series analysis in clinical microbiology, refer to Monnet et al.
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A DR model states how an output (resistance rate) is linearly related to current and past values of one or more inputs (fluoroquinolone use). It can be written as:
where Y t is the hospital resistance rate at month t, C is a constant, f 1 to f n are n linear transfer functions that can be written for each fluoroquinolone i from 1 to n as:
and N t is a disturbance series (what is left unexplained of Y t after taking inputs into account); in a dynamic regression model, N t is autocorrelated and is introduced as an ARIMA model to account for autocorrelation.
We followed the method developed by Pankratz 29 to build a DR model. As a preliminary step, we ruled out feedback from output to inputs, estimating the following model for each i of the n fluoroquinolones:
To rule out feedback, we checked that none of the d k coefficients was statistically significant, using individual Wald t-tests and a Fisher joint test.
We then identified linear transfer functions and ARIMA disturbance series using Pankratz's identification rules. Model parameters were estimated using the method of maximum likelihood. Finally, we checked model adequacy on the residuals of N t : no residual autocorrelation, normal distribution of residuals and residuals not greater than twice their standard deviation. We selected the best model as the one fulfilling all of the checking stages and with the smallest Akaike Information Gallini et al.
Criterion (AIC). We built three DR models stating how hospital resistance is linked, respectively, to consumption of fluoroquinolones in TUH, the community and in both areas.
Lastly, we performed one step ahead resistance forecasts for the year 2008 using the ARIMA predictions obtained for the input series. The resistance forecasts were compared with the actual rates for the first five months of 2008.
Statistical analysis was performed with SAS/ETS # 'proc arima' (version 9.1, SAS Institute, Cary, NC, USA).
Results
Descriptive analysis
On average, 458 strains of E. coli were isolated every month in TUH. Most of the isolates were cultured from urine (62%), genital fluids (9%) or pus (8%).
The mean ciprofloxacin-resistant E. coli percentage in TUH increased during the period, from 12.3% in 2004 to 15.2% in 2007 ( Table 1) . The chronological series, presented in Figure 1 , showed some seasonal patterns for the years 2004 and 2005 that were not seen in the subsequent years.
During the period of the study, mean fluoroquinolone use was 82.9 DDDs/1000 inpatient days in TUH and 2.6 DDDs/1000 inhabitants/day in the community (Table 1) Table 2 (model A). This DR model fulfilled checking controls and explained 46% of the observed variations in the ciprofloxacin resistance series. One can interpret these findings, for instance, by saying an increase of 1 DDD/1000 inpatient days in ciprofloxacin use was related, with an average lag of 4 months, to an increase of 0.13% in ciprofloxacin resistance, taking into account past values of resistance and consumption of other fluoroquinolones.
Influence of community fluoroquinolone use
Parameters of the identified model are presented in Table 2 (model B). Only the previous year's values of levofloxacin use Fluoroquinolone consumption and ciprofloxacin-resistant E. coli were significantly associated with resistance evolution. An increase of 1 DDD/1000 inhabitants/day in levofloxacin use was associated with a rise of 6% in the resistance rate the next year.
Influence of hospital and community fluoroquinolone use
Taking into account both hospital and community fluoroquinolone consumption, only the use of levofloxacin in the community 12 months ago remained statistically associated with an increase in resistance, taking into account past values of resistance. As the use of levofloxacin in TUH 4 months ago was nearing the statistical boundary and may contribute more directly to the generation of resistant strains in the hospital, we decided to include this parameter in the final model.
The data are presented in Table 2 (model C). Model C was the best-fitting model and allowed us to explain around 50% of the resistance variability.
Predictions
Using parameters identified in model C and ARIMA forecasts for inputs for the year 2008, we predicted the resistance rate for a 12 month-period ( Figure 4 Gallini et al.
Discussion
Ciprofloxacin-resistant E. coli in TUH increased strongly during the first years of the millennium [on average from 8% in 2003 (data not shown) to 16% in 2008]. This trend is consistent with data collected by the European Antibiotic Resistance Surveillance System (EARSS). In 2007, FQ-R E. coli rates ranged from 7% in Norway to 53% in Turkey. 30 In the French EARSS collection, 14.8% of E. coli isolates were resistant to fluoroquinolones and 2.5% were of intermediate susceptibility. In our study, the resistance series displayed seasonal variations in 2004-05 that declined in later years. Unfortunately, we have not been able to compare these patterns with other series as resistance is reported yearly in the literature.
France is well known for its high antibiotic consumption. In 2002, France was ranked first for inpatient use 31 and seventh for outpatient use of fluoroquinolones in Europe. Fluoroquinolone consumption and ciprofloxacin-resistant E. coli
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In 2007, consumption of quinolones represented around 7% of the total consumption of antibiotics in France (A. Gallini and R. Bourrel, personal data). During our study period, outpatient consumption in the Midi-Pyrénées region was higher than the mean reported by the European Surveillance of Antimicrobial Consumption (ESAC) group for France in 2003: 2.6 versus 2.0 DDDs/1000 inhabitants/day (wholesalers' data, using the 2004 new DDD for levofloxacin). 32 This difference can be attributed to variations in consumption among French regions. In 2007, the Midi-Pyrénées region ranked first out of the 22 French regions for quinolone consumption in the community, taking into account regional differences in age structures (A. Gallini and R. Bourrel, personal data).
The use of available data is one of the strengths of our study. It demonstrates that this modelling may be achieved on a routine basis. However, the use of data not specifically designed for our objectives raises several issues, which are discussed below.
Dispensing data or reimbursement claims were used as proxies for fluoroquinolone consumption. This may have led to overestimation of fluoroquinolone use (non-consumption of dispensed antibiotics, non-consumption of the entire drug package in the community). Less likely, some situations may underestimate consumption in the community, such as the use of a leftover fluoroquinolone treatment; dispensing without a medical prescription; or dispensing without a reimbursement claim (these last two situations are thought to be very unusual in France). However, these limitations did not affect the time-series evolution that was of interest in this study.
Taking into account the changes in resistance and past values of fluoroquinolone consumption allowed us to explain around 50% of the variation in resistances, suggesting that fluoroquinolone use is the main factor involved in bacterial resistance to ciprofloxacin. A dynamic regression model can handle the use of several antimicrobials, quantify the effect of antimicrobial consumption on resistance and estimate the delay between variations in use and subsequent variations in resistance. 22 Additionally, it is possible to make predictions of future resistance levels. Nonetheless, as this was an ecological study it was more sensitive to bias than individual-level studies 33 and did not address individual risk factors for resistance. 34 In particular, it was impossible to study the effects of some of the factors already known to affect the emergence or dissemination of bacterial resistance, such as inappropriate antibacterial use (i.e. inappropriate choice of antibiotic, dose or length of treatment), hygiene practices (i.e. poor hand-washing or sanitation practices) or individual factors identified in case -control studies (i.e. age, comorbidities, immunosuppression, the presence of urinary catheters, nosocomial infections or hospitalization in an intensive care unit). 4,8,35 -39 In addition, some studies found that high levels of consumption of other antibiotics were associated with high levels of resistance to fluoroquinolones in E. coli, 24 most probably because of cross-resistance to antimicrobials. 2, 13, 40, 41 We have not been able to examine this relationship.
Interestingly, the influence of fluoroquinolone use in the community seemed to have a stronger influence on hospital ciprofloxacin resistance than inpatient fluoroquinolone consumption. To our knowledge, this is the first published study to have used time-series methods, focusing both on inpatient and outpatient use in relation to FQ-R E. coli in hospital. Previously, only two ecological studies had assessed this relationship, but they used different methods and had discordant findings. Bergman et al. 24 studied the influence of consumption of various antibiotics in the community on the susceptibility of E. coli to various antibiotics between 1997 and 2005 in 20 hospital districts in Finland. Resistance to fluoroquinolones (ciprofloxacin or levofloxacin) was found to be related to amoxicillin consumption, but there was no significant association with fluoroquinolone use. In this Finnish area, fluoroquinolone use was much lower than in our study, as was the resistance rate (3.5% in 2005). The other study, by MacDougall et al., 10 did not report a significant correlation between hospital fluoroquinolone use and resistance in 17 hospitals in 2000 in the USA, but found a positive correlation between community fluoroquinolone use and hospital resistance. One possible explanation is that the greater exposure to fluoroquinolones in the community may lead to a larger reservoir of resistant organisms in outpatients, spreading in the community and detected in hospitals. In our study, 22% of the E. coli isolates tested in TUH's bacteriology laboratory came directly from outpatients through the emergency departments or outpatient clinics. Levofloxacin consumption in the community was one of the strongest predictors of resistance to ciprofloxacin in our hospital. This finding is consistent with MacDougall's results, which suggested that population density may appear as a confounder in this relationship as population density was both correlated to consumption of levofloxacin in the community and to resistance in hospitals. Unfortunately, we were not able to investigate this hypothesis in our context.
Conclusions
This ecological analysis, conducted on a university hospital scale and in a region of high fluoroquinolone consumption, suggests that hospital E. coli ciprofloxacin resistance may be linked to the consumption of fluoroquinolones within the hospital and its surrounding community. It also brings out two interesting findings: first, the important influence of levofloxacin consumption compared with the other fluoroquinolones on ciprofloxacinresistant E. coli; second, the important impact of community consumption on hospital resistance. Thus, antimicrobial consumption in the community appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals.
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